Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab with SCRT and CAPOX for Locally Advanced Rectal Cancer
NCT06802666Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in rectal cancer. Started Oct 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06802666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802666.